Anti Program Death-1/Anti Program Death-ligand 1 in Digestive Cancers

World Journal of Gastrointestinal Oncology

Volumn 7, Issue 8, 2015, Pages 95-101

  de Guillebon, Eléonore ^a   Roussille, Pauline ^a   Frouin, Eric ^a,b   Tougeron, David ^a,b  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE POITIERS   (France)

Author keywords

Antibody; Digestive cancer; Program death 1; Program death ligand 1

Indexed keywords

EID: 84962389582     PISSN: None     EISSN: 19485204     Source Type: Journal    
DOI: 10.4251/wjgo.v7.i8.95     Document Type: Article

References (22)

1. 1 Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454 [PMID: 22658127 DOI: 10.1056/NEJMoa1200690]
2. 2 Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22: 329-360 [PMID: 15032581 DOI: 10.1146/annurev.immunol.22.012703.104803]
3. 3 Badoual C, Combe P, Gey A, Granier C, Roussel H, De Guillebon E, Oudard S, Tartour E. [PD-1 and PDL-1 expression in cancer: significance and prognostic value]. Med Sci (Paris) 2013; 29: 570-572 [PMID: 23859507 DOI: 10.1051/medsci/2013296005]
4. 4 Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704 [PMID: 18173375 DOI: 10.1146/annurev.immunol.26.0 21607.090331]
5. 5 Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723 [PMID: 20525992 DOI: 10.1056/NEJMoa1003466]
6. 6 Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526 [PMID: 21639810 DOI: 10.1056/NEJMoa1104621]
7. 7 Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-2465 [PMID: 22658128 DOI: 10.1056/NEJMoa1200694]
8. 8 Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014; 515: 558-562 [PMID: 25428503 DOI: 10.1038/nature13904]
9. 9 Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8: 793-800 [PMID: 12091876 DOI: 10.1038/nm730]
10. 10 Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, Zlobec I, Eppenberger-Castori S, Tzankov A, Rosso R, Zuber M, Muraro MG, Amicarella F, Cremonesi E, Heberer M, Iezzi G, Lugli A, Terracciano L, Sconocchia G, Oertli D, Spagnoli GC, Tornillo L. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 2013; 49: 2233-2242 [PMID: 23478000 DOI: 10.1016/j.ejca.2013.02.015]
11. 11 Gatalica Z, Snyder CL, Yeatts K, Xiao N, Holterman D, Lynch HT. Programmed death 1 (PD-1) lymphocytes and ligand (PD-L1) in colorectal cancer and their relationship to microsatellite instability status. Available from: URL: http://meetinglibrary.asco.org/content/133958-144
12. 12 Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, Nakamura S, Enomoto K, Yagita H, Azuma M, Nakajima Y. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007; 13: 2151-2157 [PMID: 17404099 DOI: 10.1158/1078-0432.CCR-06-2746]
13. 13 Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, Mizuno T, Yoriki R, Kashizuka H, Yane K, Tsushima F, Otsuki N, Yagita H, Azuma M, Nakajima Y. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005; 11: 2947-2953 [PMID: 15837746 DOI: 10.1158/1078-0432. CCR-04-1469]
14. 14 Muro K, Bang YJ, Shankaran V, Geva R, Catenacci DVT, Gupta S, Eder JP, Berger R, Gonzalez EJ, Ray A, Dolled-Filhart M, Emancipator K, Pathiraja K, Lunceford JK, Cheng JD, Koshiji M, Chung HC. Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012. Available from: URL: http://meetinglibrary.asco.org/content/140536-158
15. 15 Lutzky J, Antonia SJ, Blake-Haskins A, Li X, Robbins PB, Shalabi AM, Vasselli J, Ibrahim RA, Khleif S, Segal NH. A phase 1 study of MEDI4736, an anti–PD-L1 antibody, in patients with advanced solid tumors. Available from: URL: http://meetinglibrary.asco.org/content/133649-144
16. 16 Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563-567 [PMID: 25428504 DOI: 10.1038/nature14011]
17. 17 Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412-7420 [PMID: 19934295 DOI: 10.1158/1078-0432.CCR-09-1624]
18. 18 Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbe C, Ferraresi V, Smylie M, Weber JS, Maio M, Konto C, Gurunath RK, de Pril V, Suciu S, Testori A. Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial. Available from: URL: http://meetinglibrary.asco.org/content/130118-144
19. 19 Granier C, Roussel H, de Guillebon E, Ladoire S, Combe P, Vano Y, Fabre E, Oudard S, Badoual C, Tartour E. Biomarkers from the tumor microenvironment to predict clinical response to checkpoint inhibitors. J OncoPathology 2014; 2 [DOI: 10.13032/ tjop.2052-5931.100111]
20. 20 Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568-571 [PMID: 25428505 DOI: 10.1038/nature13954]
21. 21 Tougeron D, Fauquembergue E, Rouquette A, Le Pessot F, Sesboüé R, Laurent M, Berthet P, Mauillon J, Di Fiore F, Sabourin JC, Michel P, Tosi M, Frébourg T, Latouche JB. Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations. Mod Pathol 2009; 22: 1186-1195 [PMID: 19503063 DOI: 10.1038/modpathol.2009.80]
22. 22 Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS, Zhang M, Papadopoulos N, Kinzler KW, Vogelstein B, Sears CL, Anders RA, Pardoll DM, Housseau F. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 2015; 5: 43-51 [PMID: 25358689 DOI: 10.1158/2159-8290.CD-14-0863]